NCT01594281 - Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) | Biotech Hunter

Enrollment

107

Participants

Timeline

Start Date

December 11, 2012

Primary Completion Date

November 30, 2016

Study Completion Date

December 5, 2017

Conditions

Proliferative Diabetic Retinopathy (PDR)

Interventions

DRUG

Ranibizumab 0.5 mg

Pre-filled syringe for intravitreal injection

PROCEDURE

Panretinal laser photocoagulation

PRP treatment following DRS guidelines

Trial Locations (23)

12203

Novartis Investigative Site, Berlin

20246

Novartis Investigative Site, Hamburg

35039

Novartis Investigative Site, Marburg

37075

Novartis Investigative Site, Göttingen

40225

Novartis Investigative Site, Düsseldorf

45122

Novartis Investigative Site, Essen

48145

Novartis Investigative Site, Münster

48149

Novartis Investigative Site, Münster

51109

Novartis Investigative Site, Cologne

52074

Novartis Investigative Site, Aachen

55131

Novartis Investigative Site, Mainz

63768

Novartis Investigative Site, Hösbach

64297

Novartis Investigative Site, Darmstadt

72076

Novartis Investigative Site, Tübingen

76133

Novartis Investigative Site, Karlsruhe

79106

Novartis Investigative Site, Freiburg im Breisgau

80336

Novartis Investigative Site, München

81675

Novartis Investigative Site, München

86156

Novartis Investigative Site, Augsburg

89075

Novartis Investigative Site, Ulm

93042

Novartis Investigative Site, Regensburg

08371

Novartis Investigative Site, Glauchau

04103

Novartis Investigative Site, Leipzig